MiRNA Sequencing and Assay Market Size and Forecast, 2027

The miRNA sequencing and assay market is expected to reach US$ 468.99 million by 2027 from US$ 192.31 million in 2019; it is estimated to grow at a CAGR of 11.9% from 2020 to 2027.

miRNA is a small non-coding RNA molecule of 20–30-nucleotide length, and it plays an important role in gene regulation. As it is partially complementary to messenger RNA (mRNA), it serves a major function of down-regulating the gene expression, which makes it a key controller of important cellular functions. miRNAs are associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis. Thus, extensive research is being conducted to identify new miRNAs. The growth of the miRNA sequencing and assay market is mainly attributed to the factors such widening range of miRNA applications and rise in funding for genomics research. However, challenges related to delivery, efficacy, and specificity of miRNA-based therapeutics is projected to deter the market growth.

Lucrative Regionsfor miRNA Sequencing And Assay Market

Get more information on this report : Request Free Sample PDF

Market Insights

Widening Range of MicroRNA Applications

miRNAs are a group of non-coding and small RNA molecules of 20–30-nucleotide length. These molecules bind to a target messenger RNA (mRNA) and lead to gene silencing, thereby controlling gene expression. Thus, they play a critical role in cell physiology and development. miRNAs regulate all cellular functions such as cell proliferation, differentiation, and apoptosis. Being involved in the process of differentiation, they play a crucial role in offering tissue identity. Hence, miRNAs are thought to be a useful marker in identifying cell types.

Further, miRNAs are also associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis. A few of them can act as oncogenes (oncomiRs), while several other act as tumor suppressor miRNAs. The altered expression of miRNAs is correlated with the occurrence of different types of cancer. The potential of miRNAs, combined with next-generation sequencing technologies, as a new class of cancer biomarkers is being explored. They are predicted to have a vital role to play in assessing development, progression, prognosis, diagnosis, and treatment of cancer. Moreover, several classes of miRNAs have also emerged as promising biomarkers for infectious diseases caused by pathogens, including HIV, Hendra virus, tuberculosis, and malaria.

Furthermore, discovery regarding the role of miRNAs in disease development have made miRNAs a key target of novel therapeutic approaches. Several miRNA-targeted therapeutics against the diseases such as cancer and hepatitis have reached the clinical phase. For instance, Santaris Pharma has developed a therapeutic molecule named Miravirsen that targets miR-122 for the treatment of hepatitis C virus (HCV) infection; the molecule is in the Phase II clinical trial. Therefore, the growing range of applications of miRNAs is driving the growth of the miRNA sequencing and assay market.

Product-Based Insights

The miRNA sequencing and assay market, by product, is segmented into library preparation and consumables. The consumables segment held a larger share of the market in 2019, whereas the library preparation segment is anticipated to register a higher CAGR in the market during the forecast period.

miRNA Sequencing and Assay Market, by Product – 2019 and 2027

Get more information on this report : Request Free Sample PDF

Technology-Based Insights

Based on technology, the miRNA sequencing and assay market is segmented into sequencing by synthesis, nanopore, and ion semiconductor sequencing. The sequencing by synthesis segment held the largest share of the market in 2019; however, the nanopore segment is expected to register the highest CAGR in the market during 2020–2027.

End User-Based Insights

Based on end user, the miRNA sequencing and assay market is segmented into research institute, academia, and CROs. The research institute segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during 2020–2027.

Strategic Insights

Collaboration is one of the major strategies adopted by the miRNA sequencing and assay market players to enlarge customer base worldwide, which also permits them to maintain their brand name globally.

miRNA Sequencing and Assay Market – by Product

• Library Preparation
• Consumables

miRNA Sequencing And Assay Market – by Technology

• Sequencing by Synthesis
• Nanopore
• Ion Semiconductor Sequencing

miRNA Sequencing and Assay Market – by End User

• Research Institute
• Academia
• CRO

miRNA Sequencing and Assay Market – by Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of Asia Pacific
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
• South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America

Company Profiles

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Qiagen
• Perkin Elmer Inc.
• Takara Bio Inc.
• New England Biolabs
• NorgenBiotek Corp
• TriLinkBioTechnologies Inc
• Lexogen GmbH
• Oxford Nanopore Technologies